EUVIMEDEUVIMED entdecken
Open Access

Longitudinal, Retrospective Use of a Circulating Tumor DNA Methylation Signature Successfully Captures Small Cell Evolution in a Patient With Metastatic EGFR-Mutant Non–Small Cell Lung Cancer

Tejas Patil iD, Amy Guimarães-Young iD, Jill Tsai, Dara L Aisner iD, Leslie Bucheit iD, Anton Valouev

JCO Precision Oncology · 2026-04 · 10 (4)

DOI: 10.1200/po-25-00795 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2026-04. Verfasst von Tejas Patil und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Circulating tumor DNA (ctDNA) offers a minimally invasive approach for longitudinal tumor monitoring in EGFRm NSCLC.Although genomic ctDNA assays have been used to detect resistance mechanisms, including small cell transformation, 11 ,12 the challenge is that small cell transformation is often accompanied by widespread epigenetic (non-CpG methylation) reprogramming within affected cells.13 Therefore, methylation-based ctDNA assays can provide complimentary information to genomic testing and improve detection of t-SCLC.[11][12][13] Here, we describe a patient with EGFRm NSCLC who developed t-SCLC and demonstrate how longitudinal use of plasma-based methylation analysis successfully corresponded with small cell evolution throughout the disease course. Results CaseA 52-year-old woman with no smoking history presented with 3 weeks of progressive shoulder pain, dry cough, and dyspnea, and on examination was found to have decreased breath sounds along the right side with dullness to percussion up to the third intercostal space.Chest computed tomography (CT) imaging revealed extensive right-sided pleural thickening, pleural nodularity, and a large pleural effusion.A right-sided thoracentesis demonstrated atypical cells, suspicious for adenocarcinoma.Subsequent positron emission tomography (PET)/CT showed right-sided pleural-based disease (maximum standardized uptake value of 7.6 at the lung apex) along with mediastinal and precrural lymph node involvement.An brain MRI revealed no intracranial metastasis.

Autor:innen und Institutionen

  • Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO.
  • Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO.
  • Guardant Health, Inc, Redwood City, CA.

ORCID-Profile: Tejas Patil, Amy Guimarães-Young, Dara L Aisner, Leslie Bucheit

Zitieren

APA

Patil, T., Guimarães-Young, A., Tsai, J., Aisner, D. L., Bucheit, L., & Valouev, A. (2026). Longitudinal, Retrospective Use of a Circulating Tumor DNA Methylation Signature Successfully Captures Small Cell Evolution in a Patient With Metastatic EGFR-Mutant Non–Small Cell Lung Cancer. JCO Precision Oncology, 10(4). https://doi.org/10.1200/po-25-00795

Vancouver

Patil T, Guimarães-Young A, Tsai J, Aisner DL, Bucheit L, Valouev A. Longitudinal, Retrospective Use of a Circulating Tumor DNA Methylation Signature Successfully Captures Small Cell Evolution in a Patient With Metastatic EGFR-Mutant Non–Small Cell Lung Cancer. JCO Precision Oncology. 2026;10(4). doi:10.1200/po-25-00795

BibTeX
@article{Patil2026,
  author = {Patil, Tejas and Guimarães-Young, Amy and Tsai, Jill and Aisner, Dara L and Bucheit, Leslie and Valouev, Anton},
  title = {Longitudinal, Retrospective Use of a Circulating Tumor DNA Methylation Signature Successfully Captures Small Cell Evolution in a Patient With Metastatic EGFR-Mutant Non–Small Cell Lung Cancer},
  journal = {JCO Precision Oncology},
  year = {2026},
  volume = {10},
  number = {4},
  doi = {10.1200/po-25-00795}
}
Kostenlos starten →